On April 3 2026, LightStim, alongside Hand & Stone Massage and Facial Spa, announced the national rollout of their FDA-cleared Elipsa device.
The Elipsa device is now FDA-cleared to treat fine lines and wrinkles on the entire face and mild to moderate inflammatory acne. The device features LightStim's patented MultiWave Technology, delivering multiple wavelengths of light simultaneously to optimize treatment performance and support healthier-looking skin.
The expansion follows a successful pilot program that demonstrated strong guest adoption and visible treatment outcomes for franchise owners and strengthens the partnership
"Elipsa's touchless system gives our estheticians across 600+ locations the space to be fully present with every guest, while LED therapy delivers in the background. At Hand & Stone, our goal is to give every guest the best hour of their month, and Elipsa has earned its place in that experience," said Lisa Rossmann, Chief Concept Officer at Hand & Stone."
The integration of Elipsa into Hand & Stone's facial offerings reflects both brands' commitment to science-backed innovation and accessible, results-driven skincare. By pairing LightStim's clinical expertise with Hand & Stone's network of 600+ locations and licensed estheticians, the partnership makes professional LED therapy available to guests at scale.
"At LightStim, we have always believed that light therapy should be both clinically grounded and deeply accessible," said Joniann Marchese, President of LightStim. "Our partnership with Hand & Stone reflects a shared commitment to elevating professional skincare through science-backed innovation. Seeing Elipsa embraced nationally represents a broader shift toward intelligent, results-driven treatments that support both the provider and the guest experience."
Elipsa treatments are now available at participating Hand & Stone locations nationwide. Guests may also purchase select LightStim at-home devices through Hand & Stone spas, extending the benefits of LED therapy beyond the treatment room.
